WO2017080669A1 - Préparation pharmaceutique efficace contre les troubles liés au vieillissement - Google Patents

Préparation pharmaceutique efficace contre les troubles liés au vieillissement Download PDF

Info

Publication number
WO2017080669A1
WO2017080669A1 PCT/EP2016/001888 EP2016001888W WO2017080669A1 WO 2017080669 A1 WO2017080669 A1 WO 2017080669A1 EP 2016001888 W EP2016001888 W EP 2016001888W WO 2017080669 A1 WO2017080669 A1 WO 2017080669A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical preparation
liquid
use according
exosomes
production method
Prior art date
Application number
PCT/EP2016/001888
Other languages
English (en)
Inventor
Peter Wehling
Julio Reinecke
Original Assignee
Orthogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orthogen Ag filed Critical Orthogen Ag
Priority to IL259007A priority Critical patent/IL259007B1/en
Priority to MA042963A priority patent/MA42963A/fr
Priority to MX2019001948A priority patent/MX2019001948A/es
Priority to PCT/EP2017/000574 priority patent/WO2018033226A1/fr
Priority to KR1020197003441A priority patent/KR20190049690A/ko
Priority to CN201780003804.9A priority patent/CN108348548A/zh
Priority to PE2019000304A priority patent/PE20190627A1/es
Priority to US16/325,870 priority patent/US20190290689A1/en
Priority to CR20190139A priority patent/CR20190139A/es
Priority to BR112019002080-2A priority patent/BR112019002080A2/pt
Priority to AU2017313163A priority patent/AU2017313163B2/en
Priority to EP20155846.7A priority patent/EP3695845A1/fr
Priority to CA3033045A priority patent/CA3033045A1/fr
Priority to SG11201900866YA priority patent/SG11201900866YA/en
Priority to JP2019508969A priority patent/JP2019528281A/ja
Priority to EP17728051.8A priority patent/EP3352769A1/fr
Priority to EA201890841A priority patent/EA201890841A1/ru
Priority to CR20190091A priority patent/CR20190091A/es
Priority to CN201780003805.3A priority patent/CN108348549A/zh
Priority to SG11201901085RA priority patent/SG11201901085RA/en
Priority to MX2019001949A priority patent/MX2019001949A/es
Priority to EP20163717.0A priority patent/EP3763377A1/fr
Priority to MA042964A priority patent/MA42964A/fr
Priority to US16/325,945 priority patent/US20210290671A1/en
Priority to JP2019508931A priority patent/JP2019529357A/ja
Priority to EP17728052.6A priority patent/EP3352770A1/fr
Priority to PE2019000361A priority patent/PE20190517A1/es
Priority to EA201890840A priority patent/EA201890840A1/ru
Priority to BR112019002982-6A priority patent/BR112019002982A2/pt
Priority to TW106115815A priority patent/TW201806605A/zh
Priority to CA3033899A priority patent/CA3033899A1/fr
Priority to AU2017313164A priority patent/AU2017313164B2/en
Priority to TW106115816A priority patent/TW201806606A/zh
Priority to PCT/EP2017/000581 priority patent/WO2018033227A1/fr
Priority to KR1020197004442A priority patent/KR20190046793A/ko
Publication of WO2017080669A1 publication Critical patent/WO2017080669A1/fr
Priority to PCT/EP2017/000994 priority patent/WO2018033249A1/fr
Priority to US16/325,944 priority patent/US20190231816A1/en
Priority to IL259006A priority patent/IL259006A/en
Priority to HK18114754.7A priority patent/HK1255619A1/zh
Priority to HK19101111.1A priority patent/HK1259143A1/zh
Priority to HK19101113.9A priority patent/HK1258712A1/zh
Priority to PH12019550017A priority patent/PH12019550017A1/en
Priority to PH12019550022A priority patent/PH12019550022A1/en
Priority to CONC2019/0001232A priority patent/CO2019001232A2/es
Priority to CONC2019/0001265A priority patent/CO2019001265A2/es
Priority to CL2019000419A priority patent/CL2019000419A1/es
Priority to CL2019000420A priority patent/CL2019000420A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Definitions

  • the present invention relates to the field of ageing, in particular to the treatment of age-related disorders and provides a pharmaceutical preparation for such treatment.
  • ageing of the human population and ageing-associated disorders is a global challenge. Many industrialised countries have an increasingly ageing population, and also in developing countries the proportion of elderly people is expected to rise steeply. On a biological level ageing may be defined as a progressive deterioration over time of an organism and its individual cells, tissues and organs. Such deterioration may lead to certain age-related disorders. It has been estimated that by 2050 the number of people aged 60 and older worldwide will approximately double as compared to its current figure of around 1 1 %.
  • Oxidative damage to cells and cell components has also been implicated in ageing and certain disorders, and thus the lack of sufficient repair, such as the impaired expression or activity of antioxidant enzymes.
  • Cellular senescence has also been linked to the shortening of telomeres, which may act as a molecular clock and thus might be the cause of certain disorders linked with senescence. Where cells become incapable of maintaining a sufficient rate of cell division, a lack of renewal of tissues might promote age-related disorders. Excessive cell death such as apoptosis may also contribute to ageing, senescence and associated disorders.
  • Another ageing theory focuses on excessive (even if subtle) inflammation, which exerts harmful effects in advanced age.
  • the immune system is also subject to senescence, one characteristic being "immunosenescence" associated with a reduced sensitivity to vaccination.
  • UV radiation is inter alia present in sunlight. It has a wavelength below that of visible light. Biologically, the UV-A band (defined by ISO-21348 as 315 to 400 nm), the most long-wave part of the UV spectrum, and the neighbouring UV-B band (280 to 315 nm) are most important, whereas UV radiation having a shorter wavelength (UV-C) is practically absorbed by the ozone layer and the earth's atmosphere. UV radiation is able to trigger chemical reactions. Whereas it has certain beneficial actions on the human body, it is also dangerous since it causes damage, in particular to the skin and the eyes. UV radiation (all bands) is known to damage collagen and elastin fibres, which gives rise to skin ageing (photoageing), whose signs may include loose skin, dryness and/or wrinkling.
  • UV-B radiation causes the formation of pyrimidine dimers (in particular thymine dimers), a process that is also known as direct DNA damage.
  • the formed lesions alter the DNA structure and may be repaired by a mechanism known as Nucleotide Excision Repair. If unrepaired, the lesions are mutagenic.
  • UV radiation also causes the production of reactive oxygen species/free radicals, which gives rise to oxidative damage, a process known as indirect DNA damage. Both direct and indirect DNA damage contribute to the formation of cancer. It is therefore apprehensible that broad-spectrum UV radiation is recognised as a carcinogen by the World Health Organisation.
  • Type 1 and Type 2 Two major types of immune processes are commonly distinguished, Type 1 and Type 2.
  • Type 1 T helper cells T h 1 cells
  • Type 1 macrophages M1
  • T h 2 cells Type 2 T helper cells
  • M2 Type 2 macrophages
  • Typical cytokines associated with Type 1 processes are IFN- ⁇ and IL-2.
  • Type 1 immune response maximise the cellular killing ability.
  • damage to the organism may occur, e.g. when directed to autoantigens type 1 diabetes, and more generally ageing may be accelerated due to excessive and/or chronic inflammation.
  • the preponderance of Type 1 immune processes may e.g. be a preponderance of Type 1 over Type 2 immune processes.
  • Such an imbalance in immune processes might be countered by promoting other immune processes (e.g. Type 2) or inhibiting Type 1 immune processes, facilitating the resolution of inflammation.
  • neurodegeneration such as in Alzheimer's disease, Parkinson's disease and multiple sclerosis a role of macrophages (such as microglia) has been described.
  • Cellular senescence is a phenomenon that leads to the inability of isolated cells to divide perpetually and makes them arrest after a certain number of divisions.
  • a cellular staining assay that detects senescence-associated ⁇ - galactosidase activity is commonly used (see e.g. Dimri et al. (1995) PNAS 92, 9363 to 9367).
  • Cells exhibiting a senescent phenotype may interfere with vital functions of a whole organism and thus lead to certain disorders.
  • the senescence of a whole organism is accompanied by an increased risk of certain disorders (such as diseases, complications and conditions). It is found that the incidence of certain disorders increases with age in the greater than linear fashion, for example exponentially.
  • Common specific disorders correlated with age are atherosclerosis, cardiovascular disease, cancer, hearing deficits, vision deficits, cataracts, retinal degeneration, e.g. macular degeneration, osteoporosis, type 2 diabetes, hypertension, liver failure, cachexia, kyphosis, gait disorders, tremors, ataxia, dystonia, reduced grip strength, muscle wasting and hair greying.
  • Age also promotes neurodegeneration and similar disorders, such as mild cognitive impairment, Alzheimer's disease, cerebrovascular disease, Parkinson's disease and amyotrophic lateral sclerosis.
  • a novel means for treating, preventing, inhibiting or mitigating one or more of the above-mentioned disorders, or for interfering with one or more of the biological causes of such disorders is a skin disorder, such a disorder that can be assessed by a suction elasticity measurement (e.g. by using a Cutometer®).
  • a suction elasticity measurement e.g. by using a Cutometer®.
  • such a means is fast and easy to produce and is cost effective. Also advantageously such a means should have good body compatibility.
  • a pharmaceutical preparation for use by injection into the skin wherein the pharmaceutical preparation is preparable by a production method comprising the steps of providing a liquid collected from an organism, which liquid comprises cellular constituents of blood, providing a vessel or containment means, said vessel or containment means having an internal surface, and contacting said liquid with said vessel or containment means, wherein
  • said production method further comprises the step of incubating said liquid in said vessel or containment means for an incubation time, and optionally removing cellular constituents of said liquid after said incubation,
  • said liquid comprises exosomes
  • said production method further comprises the steps of concentrating said exosomes and optionally removing cellular constituents of said liquid after said concentration, or the step of isolating said exosomes, or
  • said production method further comprises the step of avoiding incubation of said liquid, and the step of removing cellular constituents of said liquid contacted with said vessel or containment means.
  • Said production method has three alternatives (a), (b), and (c) and is in the following referred to as the "adjusted production method of the present specification".
  • the present invention may also be described as a method of treating a patient in need of such treatment by injection of a pharmaceutical preparation into the skin, wherein the pharmaceutical preparation is preparable by a production method comprising the steps of providing a liquid collected from an organism, which liquid comprises cellular constituents of blood, providing a vessel or containment means, said vessel or containment means having an internal surface, and contacting said liquid with said vessel or containment means, wherein
  • said production method further comprises the step of incubating said liquid in said vessel or containment means for an incubation time, and optionally removing cellular constituents of said liquid after said incubation,
  • said liquid comprises exosomes
  • said production method further comprises the steps of concentrating said exosomes and optionally removing cellular constituents of said liquid after said concentration, or the step of isolating said exosomes, or
  • said production method further comprises the step of avoiding incubation of said liquid, and the step of removing cellular constituents of said liquid contacted with said vessel or containment means.
  • the present invention may also be described as a method of preparing a pharmaceutical preparation for use by injection into the skin, wherein the method comprises the steps of providing a liquid collected from an organism, which liquid comprises cellular constituents of blood, providing a vessel or containment means, said vessel or containment means having an internal surface, and contacting said liquid with said vessel or containment means, wherein
  • said production method further comprises the step of incubating said liquid in said vessel or containment means for an incubation time, and optionally removing cellular constituents of said liquid after said incubation,
  • said liquid comprises exosomes
  • said production method further comprises the steps of concentrating said exosomes and optionally removing cellular constituents of said liquid after said concentration, or the step of isolating said exosomes, or (c) said production method further comprises the step of avoiding incubation of said liquid, and the step of removing cellular constituents of said liquid contacted with said vessel or containment means.
  • the production method of the present specification refers to a production method comprising the following steps: providing a blood sample collected from an organism and a vessel or container, contacting said blood sample with said vessel or a container, and incubating said blood sample in said vessel or container, wherein said blood sample is (1) a whole blood sample or (2) a whole blood sample from which erythrocytes have been depleted.
  • injection includes any administration that uses one or more sharp objects (such as needles) to allow the pharmaceutical preparation to cross the skin surface.
  • the skin surface is penetrated by a hollow needle through which the pharmaceutical preparation is administered.
  • a "cellular constituent of blood” means any cellular constituent of whole blood, whether present in large or small amounts.
  • the "liquid" is a blood sample, which is (1 ) a whole blood sample or (2) a whole blood sample from which cells have been depleted.
  • the cells that have been depleted are preferably selected from erythrocytes, leukocytes (in particular neutrophils, eosinophils, basophils, lymphocytes, B cells, T cells, NK cells and/or monocytes) and platelets. More preferably the cells that have been depleted are erythrocytes.
  • Constainment means refers to one or more containment means (preferably “container”).
  • the vessel or containment means may be the same as that/those or different than that/those in which said liquid has been collected.
  • the "internal surface" of the vessel or containment means refers to the internal surface of the vessel or containment means itself. In particular, the surface of any macroscopic particles, microscopic particles or nanoparticles that might be contained in the vessel or containment means is not considered.
  • “Incubation” or “incubating” preferably refers to (i) an incubation with a duration of at least 2 min, 3 min, 4 min, 5 min, 7 min, 10 min, 15 min, 20 min, 25 min, 30 min, 35 min, 40 min, 45 min, 50 min, 55 min, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, 4 h, 4.5 h, 5 h, 5.5 h or 6 h and/or (ii) an incubation after which a measurable change in a certain parameter has occurred with respect to the value before incubation and/or the normal value of that parameter (such as the concentration of a cytokine, the concentration of a cytokine antagonist, in particular IL-1 Ra, the concentration of exosomes and/or the concentration of a growth factor).
  • concentration of a cytokine such as the concentration of a cytokine, the concentration of a cytokine antagonist, in particular IL-1 Ra, the
  • treatment also includes prophylaxis.
  • the present invention therefore provides a pharmaceutical preparation for use by injection into the skin, wherein the pharmaceutical preparation is preparable by a production method comprising the steps of providing a blood sample collected from an organism, which blood sample is (1 ) a whole blood sample or (2) a whole blood sample from which erythrocytes have been depleted, providing a vessel or container, said vessel or container having an internal surface, and contacting said blood sample with said vessel or a container, wherein
  • said production method further comprises the step of incubating said blood sample in said vessel or container for an incubation time, and optionally removing cellular constituents of said blood sample after said incubation,
  • said blood sample comprises exosomes
  • said production method further comprises the steps of concentrating said exosomes and optionally removing cellular constituents of said blood sample after said concentration, or the step of isolating said exosomes, or
  • said production method further comprises the step of avoiding incubation of said blood sample, and the step of removing cellular constituents of said blood sample contacted with said vessel or container.
  • This embodiment may also be described as a method of treating a patient in need of such treatment by injection of a pharmaceutical preparation into the skin, wherein the pharmaceutical preparation is preparable by a production method comprising the following steps: providing a blood sample collected from an organism, which blood sample is (1 ) a whole blood sample or (2) a whole blood sample from which erythrocytes have been depleted, providing a vessel or container, said vessel or container having an internal surface, and contacting said blood sample with said vessel or a container, wherein
  • said production method further comprises the step of incubating said blood sample in said vessel or container for an incubation time, and optionally removing cellular constituents of said blood sample after said incubation,
  • said blood sample comprises exosomes
  • said production method further comprises the steps of concentrating said exosomes and optionally removing cellular constituents of said blood sample after said concentration, or the step of isolating said exosomes, or
  • said production method further comprises the step of avoiding incubation of said blood sample, and the step of removing cellular constituents of said blood sample contacted with said vessel or container.
  • this embodiment may also be described as a method of preparing a pharmaceutical preparation for use by injection into the skin, wherein the method comprises the following steps: providing a blood sample collected from an organism, which blood sample is (1 ) a whole blood sample or (2) a whole blood sample from which erythrocytes have been depleted, providing a vessel or container, said vessel or container having an internal surface, and contacting said blood sample with said vessel or a container, wherein
  • said production method further comprises the step of incubating said blood sample in said vessel or container for an incubation time, and optionally removing cellular constituents of said blood sample after said incubation,
  • said blood sample comprises exosomes
  • said production method further comprises the steps of concentrating said exosomes and optionally removing cellular constituents of said blood sample after said concentration, or the step of isolating said exosomes, or
  • said production method further comprises the step of avoiding incubation of said blood sample, and the step of removing cellular constituents of said blood sample contacted with said vessel or container.
  • the present invention also provides a pharmaceutical preparation for use as described above in the treatment of
  • the present invention further provides a pharmaceutical preparation for use as described above in the treatment a disorder selected from the group consisting of Lichen sclerosus et atrophicus (LSA), Ehlers-Danklos Syndrome, Elastosis actinica, Elastoidosis cutanea nodularis et cystica and Elastosis perforans serpiginosa.
  • LSA Lichen sclerosus et atrophicus
  • Elastosis actinica Elastoidosis cutanea nodularis et cystica
  • Elastosis perforans serpiginosa elasticity of the skin and/or the connective tissue is impaired.
  • disorders refers to disturbances in normal function or appearance and includes diseases, complications and conditions.
  • the use by injection into the skin or the use in the above treatment is in the following sometimes referred to as "the use according to the present invention". Accordingly the pharmaceutical preparation for use by injection into the skin or for use in the above treatment is sometimes referred to as "the pharmaceutical preparation for use according to the present invention"
  • said oxidative damage is damage by reactive oxygen species.
  • Said disorder caused by DNA damage is preferably a disorder caused by UV- dependent DNA damage.
  • said disorder caused by UV-dependent DNA damage is selected from a disorder caused by pyrimidine dimers, basal-cell carcinoma, squamous-cell carcinoma and melanoma.
  • said disorder caused by impaired DNA repair is a disorder caused by deficient Nucleotide Excision Repair.
  • said disorder caused by impaired cell division is a disorder associated with (more preferably caused and/or or mimicked by) impaired division of nucleus pulposus cells.
  • said disorder caused by excessive inflammation is a non-orthopaedic disorder, a disorder not involving the nervous system and/or a disorder not involving the eye. It is preferred that said disorder caused by excessive inflammation is different from one, more than one, or all of the following disorders: rheumatism, arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, Bechterew arthritis, osteoarthritis, back symptoms, neuroorthopaedic disorders, joint disorders, intervertebral disc disorders, spinal disorders, nerve root disorders, tendon disorders, loss of cartilage, neurodermitis and alopecia.
  • said pathogenic polarisation of immune processes is a preponderance of Type 1 immune processes.
  • Type 1 immune processes are T h 1 and/or M1 processes, and more preferably they are T h 1 and M1 processes.
  • Preponderance of Type 1 immune processes includes the meaning “preponderance of Type 1 over Type 2 immune processes", wherein said Type 2 immune processes are preferably T h 2 and/or M2 processes and more preferably T h 2 and M2 processes.
  • Preponderance of Type 1 immune processes also includes the meanings "excessive Type 1 immune processes” and “impaired other immune processes”, e.g. "impaired Type 2 immune processes” (with preferred embodiments as set out above). Said cell death is preferably apoptosis.
  • said mutation in said genetically altered mouse is preferably in the Ercd gene. More preferably it is Ercd " ' " or Ercc1 " A .
  • said disorder caused by collagen damage and/or elastin damage is selected from loose skin, dryness and wrinkling.
  • a disorder caused by collagen damage and/or elastin damage may also be generally described as skin ageing.
  • a preparation prepared according to the adjusted production method of the present specification is capable of surprisingly improving skin parameters that can be assessed by a suction elasticity measurement using a Cutometer®, when being injected into the skin, in particular elasticity.
  • Cutometer® such as the Cutometer® Dual MPA580
  • R0 Represents the passive behaviour of the skin to force (firmness), looks at the maximum amplitude.
  • R1 Ability of the skin to return to its original state.
  • R2 Gross elasticity, the higher the value the more elastic the curve.
  • R3 Maximum amplitude of the last suction curve after repeated suction. "Tiring effects" (fatigue) of the skin are visible, as the amplitude increases with each new suction.
  • R5 Net elasticity, the higher the value, the more elastic is the skin.
  • R6 Portion of the visco-elasticity on the elastic part of the curve. The smaller the value the higher the distensibility of the elastine fibres.
  • R7 Portion of the elasticity compared to the complete curve, the higher the value, the more elastic the skin.
  • R8 Skin recovery, the closer the value is to R0, the better is the ability of the skin to return to its original state.
  • R9 Represents tiring effects of the skin after repeated suction and release of the skin. The smaller R9, the smaller the tiring effects.
  • F2 Area above the upper envelope-curve showing tiring effects after repeated suction.
  • F3 Area within the envelope curves, represents the skin fatigue.
  • F4 Area under the upper envelope-curve. The smaller F4 the more the skin resists to the suction (skin firmness).
  • Viscoelastic recovery (overall elasticity), will increase with more elasticity of the skin.
  • R0 is considered to be the most important parameter (the lower the value, the higher is the elasticity).
  • R5 is considered to be the second most important parameter.
  • a preparation prepared according to the production method of the present specification counteracts the harmful effects of UV radiation on cells, has a stronger anti-inflammatory effect in older patients than in younger patients, contains an even more favourable ratio anti-inflammatory to inflammatory components in older patients than in younger patients, induces a shift in immune system function from inflammatory to regenerative and anti-inflammatory, stimulates an anti-apoptotic pathway and increases cell division, which serves as the basis of the present invention.
  • the preparation prepared according to the production method of the present specification or the adjusted production method of the present specification is thus a pharmaceutical preparation, and it may be used as a novel means for treating, preventing, inhibiting or mitigating the above-mentioned disorders or in interfering with the biological causes of the aforementioned.
  • the pharmaceutical preparation for use according to the present invention is preparable by a production method which comprises: providing a liquid collected from an organism, which liquid comprises cellular constituents of blood, providing a vessel or containment means, said vessel or containment means having an internal surface, and contacting said liquid with said vessel or containment means, wherein (a) said production method further comprises the step of incubating said liquid in said vessel or containment means for an incubation time, and optionally removing cellular constituents of said liquid after said incubation, (b) said liquid comprises exosomes, and said production method further comprises the steps of concentrating said exosomes and optionally removing cellular constituents of said liquid after said concentration, or the step of isolating said exosomes, or (c) said production method further comprises the step of avoiding incubation of said liquid, and the step of removing cellular constituents of said liquid contacted with said vessel or containment means.
  • said production method comprises: providing a blood sample collected from an organism, providing a vessel or container, said vessel or container having an internal surface, and contacting said blood sample with said vessel or a container, wherein (a) said production method further comprises the step of incubating said blood sample in said vessel or container for an incubation time, and optionally removing cellular constituents of said blood sample after said incubation, (b) said blood sample comprises exosomes, and said production method further comprises the steps of concentrating said exosomes and optionally removing cellular constituents of said blood sample after said concentration, or the step of isolating said exosomes, or (c) said production method further comprises the step of avoiding incubation of said blood sample, and the step of removing cellular constituents of said blood sample contacted with said vessel or container.
  • a pharmaceutical preparation is present, and its efficacy results from carrying out these method steps.
  • the method results in a conditioned blood sample.
  • efficacy is not dependent on incubation, as explained further below. Therefore according to alternative (b) incubation may be carried out or avoided, and according to alternative (c) incubation is avoided.
  • the liquid preferably blood sample
  • the liquid is a blood sample, which is a whole blood sample.
  • the blood sample may also be a fraction of whole blood.
  • erythrocytes being cells that lack a nucleus and thus gene expression ability, may be absent from the blood sample. Therefore said blood sample is alternatively a whole blood sample from which erythrocytes have been depleted (preferably completely or substantially completely, but it is alternatively envisaged that only part of the erythrocytes have been depleted), for example a buffy coat or PRP (platelet-rich plasma).
  • the production method of the present specification or the adjusted production method of the present specification preferably additionally includes the step of collecting said liquid (preferably blood sample, more preferably whole blood sample) from said organism.
  • said liquid preferably blood sample, more preferably whole blood sample
  • Said organism may or may not suffer from any of the above-mentioned disorders and cells in that organism may or may not exhibit the above-mentioned phenotype.
  • the pharmaceutical preparation prepared according to the production method of the present specification has been found to counteract the harmful effects of UV radiation on cells.
  • the cell count in cells irradiated with a combination of UV-A and UV-B radiation has been found to be higher in the presence of the pharmaceutical preparation prepared according to the production method of the present specification than in its absence.
  • the magnitude of his effect was dependent on the incubating step. Therefore incubation of the liquid (preferably blood sample, more preferably whole blood sample) leads to the formation of components efficacious in promoting the survival and/or proliferation of UV-irradiated cells.
  • the effect of the pharmaceutical preparation prepared according to the production method of the present specification namely to rescue DNA damage caused by UV, is the same as that of a functional Nucleotide Excision Repair system. Therefore, without being bound to theory it may be concluded that the pharmaceutical preparation for use according to the present invention stimulates Nucleotide Excision Repair. More generally, it may be concluded that the pharmaceutical preparation for use according to the present invention has an effect on a disorder caused by impaired DNA repair or accumulation of DNA damage.
  • the pharmaceutical preparation for use according to the present invention is useful in treating a disorder caused by insufficient Nucleotide Excision Repair.
  • Nucleotide Excision Repair for example Ercd " ' " mice.
  • This model shows a premature ageing phenotype and is considered to reflect normal ageing, both in mice and in other organisms, such as humans. It shows age related pathologies in coat condition, kyphosis, gait, tremors, ataxia, dystonia and grip strength. Kyphosis has further implications on osteoporosis.
  • dystonia and tremors are neurodegenerative disorders and have an impact on neurodegeneration and associated disorders like Alzheimer's disease, mild cognitive impairment, cerebrovascular disease, Parkinson's disease and amyotrophic lateral sclerosis. Gait and grip strength have an impact on muscle wasting. Moreover, neurodegeneration and associated disorders are usually linked to neuroinflammation. It can be concluded that the anti-inflammatory action of the pharmaceutical preparation for use according to the present invention is also useful in the treatment of neuroinflammation, neurodegeneration and associated disorders.
  • the pharmaceutical preparation prepared according to the production method of the present specification stimulates the NF- ⁇ pathway, which is known to have anti-apoptotic effects, in particular through inducing the expression of a number of genes whose products can inhibit apoptosis (see e.g. Karin & Lin (2002) Nat Immunol 3, 221). Therefore the conclusion may be drawn that it can be used in the treatment of a disorder caused by excessive cell death.
  • the pharmaceutical preparation prepared according to the production method of the present specification has also been found to increase cell division. Accordingly it may be concluded that it has an effect on a disorder caused by impaired cell division. Since senescence and ageing may be caused by impaired cell division, this finding may contribute to explaining the general effect of the pharmaceutical preparation in age-related disorders. For example, in the age- related degeneration of intervertebral discs as a whole, the degeneration of cells of the intervertebral disc is relevant. An increased division of cells of the intervertebral disc (nucleus pulposus) may rejuvenate the intervertebral discs and may help prevent disorders of the intervertebral discs such as slipped discs in which a lack of sufficient cell division and renewal may play a role.
  • the pharmaceutical preparation for use according to the present invention may afford, for example, a simple, cost effective and/or rapid production.
  • a ready-to-use pharmaceutical preparation is realised without having to add any substances foreign to the body during production or such other substances which will have to separated again later in the production.
  • an especially body-compatible agent is produced.
  • f is smaller than or equal to 0.45 h/cm 2 , smaller than or equal to 0.4 h/cm 2 , smaller than or equal to 0.35 h/cm 2 , smaller than or equal to 0.3 h/cm 2 , smaller than or equal to 0.25 h/cm 2 , smaller than or equal to 0.24 h/cm 2 , smaller than or equal to 0.23 h/cm 2 , and in particular smaller than or equal to 0.22 h/cm 2 .
  • This is useful for ensuring that the pharmaceutical preparation has no undesired inflammatory potential.
  • values for f in the range of 0.04 to 0.25 h/cm 2 , 0.05 to 0.24 h/cm 2 , 0.06 to 0.23 h/cm 2 and in particular 0.07 to 0.22 h/cm 2 , whereas in some instances ranges from 0.1 to 0.22 h/cm 2 , 0.12 to 0.22 h/cm 2 or 0.14 to 0.22 h/cm 2 may also be used.
  • Exosomes are small vesicles secreted from cells into their environment. Exosomes are for example contained in biological liquids such as serum, urine, saliva, peritoneal-, cerebrospinal- and synovial liquids. Most types of cells looked at are able to secrete exosomes. The secretion occurs through release through/from the cell's plasma membrane. Depending on the cell type in which they are generated, exosomes contain inter alia a variable combination of proteins. In the following, the term "exosomes" preferably additionally comprises other extracellular vesicles (EV).
  • EV extracellular vesicles
  • exosomes have been surprisingly found by the present inventors to exhibit a number of relevant effects (such as proliferation of cells in culture, drop in systemic CRP levels), exosomes may be concentrated or isolated after conditioning, but alternatively exosomes existing in the blood may be concentrated or isolated without conditioning in order to achieve beneficial effects.
  • the production method before the step of concentrating or isolating said exosomes, further comprises the step of incubating said liquid (preferably blood sample) in said vessel or containment means for an incubation time, or the step of avoiding incubation of said liquid (blood sample). Concentrating or isolating is useful to further increase the efficacy.
  • incubation may be avoided in certain embodiments, in accordance with alternative (c) of the adjusted production method of the present specification.
  • the step of removing cellular constituents of the liquid is always carried out. Such a step of removing cellular constituents is often beneficial in all alternatives of the adjusted production method of the present specification.
  • the step of removing cellular constituents is preferably a step of removing the erythrocytes (in particular in the case when said liquid comprising cellular constituents of blood is whole blood), the platelets (in particular in the case when said liquid comprising cellular constituents of blood is whole blood or whole blood from which erythrocytes have been depleted) or the entirety of cellular constituents (in particular in the case when said liquid comprising cellular constituents of blood is whole blood or whole blood from which erythrocytes have been depleted. It is most preferred that the step of removing cellular constituents is a step of removing the entirety of cellular constituents in the case when said liquid comprising cellular constituents of blood is whole blood). Such a separation may be achieved by centrifugation, such as a short centrifugation at a low relative centrifugal force (e.g. about 10 minutes at 1000 g) or by filtration.
  • centrifugation such as a short centrifugation at a low relative centrifugal force (e
  • the step of removing cellular constituents of said liquid is optional, and alternatively it is also envisaged to include a step of refraining from removing cellular constituents of said liquid (or refraining from removing those cellular constituents with specific desired functions). In particular it is envisaged to refrain from removing the erythrocytes, the platelets or the entirety of cellular constituents.
  • the adjusted production method of the present specification further comprises the step of reducing the volume of said liquid and/or the pharmaceutical preparation prepared according to the adjusted production method of the present specification is in dry form (in particular powder form).
  • Preferred ranges for the internal surface are 10 to 300 cm 2 , 15 to 200 cm 2 , 20 to 150 cm 2 , 25 to 140 cm 2 , 30 to 130 cm 2 , 35 to 120 cm 2 and in particular 40 to 1 10 cm 2 . It is preferred that said blood sample is a whole blood sample, according to embodiment (1 ) of the adjusted production method of the present specification.
  • the injection is carried out at a depth of less than 3 mm, 2.5 mm or less, 2 mm or less, 1.5 mm or less or 1 mm or less.
  • Preferred depth ranges are 0.1 mm to less than 3 mm, 0.5 mm to less than 3 mm, 1 mm to less than 3 mm, 1 to 2.5 mm, 1 to 2 mm or 1 to 1.5 mm.
  • the injection into the skin is an injection into the dermis (i.e. an intradermal injection) or subcutis (i.e. a subcutaneous injection).
  • the above use/treatment involves one or more subsequent injections, wherein a time interval between consecutive injections is 1 day to 52 weeks, 2 days to 42 weeks, 3 days to 30 weeks, 4 days to 24 weeks, 5 days to 18 weeks, 6 days to 12 weeks, 1 to 8 weeks, in particular 1 to 6 weeks, 1 to 4 weeks, 1 to 3 weeks, 1 to 2 weeks, 2 to 3 weeks or 2.
  • a total of at least 3 injections is preferred, most preferably at time intervals of 2 weeks between the first and the second injection and between the second and the third injection, or preferably between any two consecutive injections.
  • the organism referred to above in the context of the pharmaceutical preparation for use according to the present invention is a human being.
  • said human being is at least 30, 35, 40, 45, 48, 50, 55, 60 or 65 years old, or 30 to 65, 35 to 60 or 40 to 55 years old.
  • the level of IL-6 is 2000 pg/ml or less (preferably 1500 pg/ml or less, 1000 pg/ml or less, 800 pg/ml or less, 700 pg/ml or less, 600 pg/ml or less and in particular 500 pg/ml or less)
  • the ratio of the levels of IL-1 Ra and IL-6, each measured in pg/ml is 3 or more, 5 or more, 7 or more, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 40 or more and in particular 50 or more,
  • the level of IL-1 Ra is 200 pg/ml or more, 300 pg/ml or more, 400 pg/ml or more, 500 pg/ml or more, 600 pg/ml or more, 800 pg/ml or more, 1000 pg/ml or more, 1200 pg/ml or more, 1400 pg/ml or more, 1600 pg/ml or more, 1800 pg/ml or more and in particular 2000 pg/ml or more,
  • the ratio of the levels of IL-1 Ra and IL-1 , each measured in pg/ml, is 10 or more, 20 or more, 30 or more, 40 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, 100 or more, 150 or more, 200 or more, 300 or more, 500 or more, 700 or more and in particular 1000 or more, or (e) the pharmaceutical preparation is free from added hyaluronic acid.
  • IL-6 is an important factor for the skin, and also for the liver.
  • the pharmaceutical preparation for use according to the present invention comprises exosomes.
  • exosomes contained in the pharmaceutical preparation for use according to the present invention have been generated during the above-mentioned incubation, if any, of the liquid (preferably blood sample, more preferably whole blood sample) collected from the organism in a vessel or containment means.
  • the average diameter of the exosomes in an exosome-containing pharmaceutical preparation for use according to the present invention is preferably between 30 and 200 nm, in particular between 50 and 190 nm, between 70 and 180 nm, between 90 and 160 nm or between 100 and 150 nm.
  • Exosomes of this size are the basis for an especially high efficacy, larger vesicle sizes may be indicative of conglomerates that contain damaged exosomes and aggregates.
  • larger exosomes may also be functional, in particular with regard to shifting the balance from Type 1 immune responses to Type 2 immune responses. This applies to exosomes with a diameter range of 200 to 5000 nm or 100 to 800 nm. These larger exosomes may be obtained by differential centrifugation.
  • the production method of the present specification or the adjusted production method of the present specification preferably further comprises the step of concentrating or isolating the exosomes after the incubation, if any, in order to further increase its efficacy.
  • Such a concentrating or isolating step may lead to two or more pharmaceutical preparations prepared according to the production method of the present specification or the adjusted production method of the present specification. These two or more pharmaceutical preparations correspond to the fractions obtained after performing such a concentrating or isolating step.
  • Concentrating or isolating the exosomes may for example be realised through centrifugation at 2,000 to 1 ,000,000 g, 10,000 to 800,000 g, 20,000 to 600,000 g, 50,000 to 400,000 g, 80,000 to 200,000 g and in particular 100,000 g, as such accelerations are especially suitable to concentrate or isolate exosomes, depending on their sizes.
  • Such a centrifugation is preferably conducted for at least 10 min, for at least 30 min, especially for at least 60 min.
  • the pellet formed by the centrifugation then contains the exosomes.
  • the concentrated or isolated exosomes are then taken up in a fluid (preferably a buffered solution such as PBS, or alternatively e.g. plasma or serum).
  • a fluid preferably a buffered solution such as PBS, or alternatively e.g. plasma or serum.
  • they are then filtrated, for example through a 0.2 pm filter.
  • the present invention also conceives a pharmaceutical preparation for use according to the present invention that does not contain exosomes.
  • a preferred pharmaceutical preparation for use according to the present invention does comprise exosomes, and in particular it may consist of exosomes.
  • serum or plasma is contained in the containing pharmaceutical preparation for use according to the present invention (which is preferred in certain cases), such serum or plasma preferably contains cytokines and/or growth factors.
  • the pharmaceutical preparation for use according to the present invention does not comprise a corticosteroid, since this may impair the efficacy of the pharmaceutical preparation, in particular due to inhibition of its senescence-rescuing effect and/or anti-apoptotic effect.
  • Incubation of the liquid is preferably carried out for an incubation time of 5 min to 22 hours, 10 min to 20 hours, 15 min to 18 hours, 30 min to 16 hours, 45 min to 15 hours, 1 to 14 hours, 2 to 13 hours, 3 to 12 hours, 4 to 1 1 hours, 5 to 10 hours or 6 to 9 hours.
  • the incubation is preferably carried out at a temperature of 0°C to 45°C, in particular at temperatures of 10°C to 43°C, 20°C to 41 °C, 30°C to 40°C, 35°C to 39°C, 36°C to 38°C or 37°C. These temperatures ensure best efficacy.
  • the incubation is carried out in the absence of added heparin. More preferably it is carried out in the absence of any added anticoagulant.
  • Suitable vessels or containment means for carrying out the production method of the present specification or the adjusted production method of the present specification are for example hypodermic needles, syringes, tubes such as vacuum tubes, microtiter plates and transfusion bags.
  • the vessel or containment means may e.g. have a diameter of 0.4 to 5 cm, 0.9 to 4 cm or 1.4 to 3.5 cm, and/or a length of 3 to 30 cm, 5 to 20 cm, 7 to 15 cm or 8 to 12 cm.
  • the vessel or containment means is cylindrical.
  • a preferred vessel or containment means has a volume of 1 ml to 1000 ml, 3 ml to 750 ml, 5 ml to 500 ml, 7 ml to 300 ml, 8 ml to 200 ml, 9 ml to 150 ml, 10 ml to 100 ml, 11 ml to 80 ml and in particular 12 ml to 70 ml, however it may also have a volume of 15 ml to 65 ml, 20 ml to 60 ml, 25 ml to 50 ml or 30 to 40 ml. preferably the ratio of internal surface and volume is 0.01 to 10 cm 2 /ml.
  • Preferred volumes of the liquid are 0.5 ml to 900 ml, 1 ml to 700 ml, 2 ml to 400 ml, 3 ml to 300 ml, 6 ml to 200 ml, 7 ml to 150 ml, 8 ml to 100 ml, 9 ml to 80 ml and in particular 10 ml to 60 ml, however it may also have a volume of 11 ml to 55 ml, 12 ml to 50 ml, 15 ml to 40 ml or 20 to 30 ml.
  • the vessel or containment means preferably include(s) a surface for contacting the liquid (preferably blood sample, more preferably whole blood sample) that comprises glass, plastic, corundum or quartz or a combination thereof.
  • a preferred plastic is selected from the group consisting of polystyrene, polycarbonate, polyethylene and polypropylene.
  • the vessel or containment means contain(s) macroscopic particles, microscopic particles or nanoparticles and during the incubation the liquid (preferably blood sample) is in contact with said particles.
  • macroscopic particles are defined as particles that are visible when viewed with the naked eye
  • microparticles are defined as particles that are too small to be visible when viewed with the naked eye but are visible when viewed with a microscope
  • nanoparticles are defined as particles that are too small to be visible when viewed with a microscope (and that are preferably larger than 1 nm).
  • Such particles serve the purpose of enlarging the surface for contacting the liquid (blood sample) (e.g.
  • the surface of the particles can optionally be modified, for example by incubation with a caustic agent such as 50% v/v chromosulphuric acid with subsequent repeated rinsing. As stated above, the surface of such particles is not considered when calculating the "internal surface" of the vessel or containment means.
  • the pharmaceutical preparation for use according to the present invention is for use by injection to the same organism from whom said liquid (preferably blood sample, more preferably whole blood sample) has been collected. In this case it is preferably an organism that suffers from one or more of the above-mentioned disorders.
  • the pharmaceutical preparation for use according to the present invention is preferably an autologous pharmaceutical preparation and not an allogeneic one, especially for reasons of safety.
  • the pharmaceutical preparation for use according to the invention is for use is in a combination therapy with one or more other effective agents.
  • Preferred other effective agents are agents effective in the treatment of one or more of the disorders mentioned above, hyaluronic acid or botulinum toxin, or a combination thereof.
  • Particularly preferred is a combination of the pharmaceutical preparation for use according to the invention, hyaluronic acid and botulinum toxin.
  • Example 1 Proliferation of cells of nucleus pulposus origin
  • ACS Human conditioned serum
  • FBS foetal bovine serum
  • Example 2 Stimulation of an anti-apoptotic pathway
  • the stimulation the NF- ⁇ pathway which has an anti-apoptotic effect, was tested by using a GFP/Luciferase reporter system by using the following samples: a pharmaceutical preparation prepared according to the production method of the present specification, which did not comprise isolating or concentrating exosomes generated during the incubation, and wherein the pharmaceutical preparation was a serum and the incubation time was 6 h ("ACS") and a control using control serum for which the production method of the present specification was not carried out ("Control").
  • the NF- ⁇ pathway was stimulated with various concentrations of IL-1 ⁇ .
  • nucleus pulposus cells were plated in 24 well plates in the absence of serum and in the presence of a pharmaceutical preparation prepared according to the production method of the present specification, which was in the form of a serum ("EOT"). EOT concentrations were 0.05%, 0.1%, 0.2%, 0.5% and 1%. One part of the EOT samples was not incubated, but processed immediately (“EOT0"). The other part of the EOT samples was incubated for six hours (“EOT6").
  • cells were irradiated with UV light (Herolab transilluminator FT- 28/312, 6 tubes cat. nr. 29 84 100, 15 W, 312 nm). The emission maximum was 312 nm. The duration of irradiation was 80 s. Cells were grown for another 2 days at 37°C, 5% C0 2 .
  • CRP C-reactive protein
  • the pharmaceutical preparation prepared according to the production method of the present specification decreases inflammation, as shown by the CRP levels, and thus counteracts a possible cause of ageing. It does even more so in older patients than in younger patients.
  • Example 5 Age-dependence of the ratio of anti-inflammatory to inflammatory components
  • Type 1 cytokines IL-2 and IFN- ⁇
  • IL-2 and IFN- ⁇ The decrease in Type 1 cytokines (IL-2 and IFN- ⁇ ) means that the injections had induced a shift of the immune system from inflammatory to regenerative/anti-inflammatory. Therefore an imbalance in immune processes due to a preponderance of Type 1 immune processes may be treated.
  • Exclusion criteria were severe chronic skin diseases e.g. psoriasis, atopic eczema (neurodermatitis) or other autoimmune skin diseases, skin cancer in the anamnesis, systemic diseases with skin involvement (SLE), pre-treatment with laser, botulinum toxin or hyaluronic acid, pregnancy, severe diet in the last 3 months or nutritional supplementary during the study duration of 24 weeks, acute infection, acne.
  • severe chronic skin diseases e.g. psoriasis, atopic eczema (neurodermatitis) or other autoimmune skin diseases, skin cancer in the anamnesis, systemic diseases with skin involvement (SLE), pre-treatment with laser, botulinum toxin or hyaluronic acid, pregnancy, severe diet in the last 3 months or nutritional supplementary during the study duration of 24 weeks, acute infection, acne.
  • the primary efficacy variable was gained in skin elasticity measured with the Cutometer®. Additional variables were corneometry (measurement of hydration), Global Aesthetic Improvement Scale (GAIS) scale (extent of improvement/no change/worse) self-assessment of ) attractiveness and a questionnaire.
  • GAIS Global Aesthetic Improvement Scale
  • the R0 value was greatly decreased by about 30%, from 0.34 to 0.24 (significant). This can be considered to be a difference representative of an age difference of two decades.
  • the R5 value was greatly increased by about 25% (significant).
  • the significant increase in elasticity might be due to an activation of fibroblasts.
  • a pharmaceutical preparation was prepared according to the adjusted production method of the present specification in the form of a serum ("ACS").
  • the incubation time t was 6 h and the internal surface A was 41 cm 2 . Being defined as t/A, f was thus 0.146.
  • ACS is capable of promoting cell proliferation in vitro.
  • different components of ACS were assessed for promoting proliferation of nucleus pulposus (NP) cells in vitro.
  • Nucleus pulposus cells were plated out in a 96 well cell culture plate at a density of ca. 4500 cells/well.
  • Cells were then fed with various components of ACS: ACS was fractionated via a size exclusion column (IZON qEV, cf. qEV Size Exclusion Columns for EV separation and purification http://www.izon.com/assets/SideColumnPDFs/qEV-Brochure-April-15.pdf). This column is capable of separating exosomes (EV) from proteins and other components.
  • the largest particles (EV) are eluted first, followed by gradually smaller ones.
  • the exact fraction number may depend on factors such as buffer, temperature and the identity of the applied fluid (e.g. serum, plasma or other fluids). However there will be at least 2 separate peaks that have pro-proliferative activity.
  • qEV columns were equilibrated with cell culture medium (DMEM, Gibco); 500 ⁇ of ACS was applied to columns and fractionated as follows. The first 1.5 ml were discarded, the following liquid was collected in 350 ⁇ fractions. Fractions were used to feed cells and numbers of cells were determined by a CCK-8 ("Cell Counting Kit-8") assay.
  • DMEM cell culture medium
  • CCK-8 Cell Counting Kit-8
  • CCK-8 provides a sensitive colorimetric assay for the determination of cell viability.
  • a highly water-soluble tetrazolium salt, WST-8 is reduced by dehydrogenase activities in cells to give an orange-colour formazan dye, which is soluble in the tissue culture media.
  • the absorption at 450 nm is proportional to active mitochondria in cells, see http://www.dojindo.eu.com/store/p/456- Cell-Counting-Kit-8.aspx.
  • the amount of the formazan dye, generated by the activities of dehydrogenases in cells is directly proportional to the number of living cells.
  • the baseline was the cell proliferation with DMEM only.
  • EV from ACS promote cell proliferation.
  • Proteins from ACS also promote cell proliferation.
  • ACS contains two groups of components which independently promote cell proliferation: EV (Exosomes) and proteins, such as growth factors.
  • a third group of components in ACS reduces cell proliferation and elutes with small components. Note: The exact fraction number of the components depends on factors such as: column size, buffer and temperature. The sequence of components does not change under non-denaturing conditions. Pooling of fractions containing EV and fractions containing proteins such as growth factors may work synergistically. Therefore it can be concluded that ACS contains 2 groups of components that independently promote cell proliferation in vitro.
  • a pharmaceutical preparation was prepared according to the adjusted production method of the present specification in the form of a serum ("ACS").
  • the incubation time t was 6 h and the internal surface A was 41 cm 2 . Being defined as t/A, f was thus 0.146.
  • ACS is capable of promoting cell proliferation in vitro. This experiment assessed ACS and other blood preparations for promoting survival of nucleus pulposus cells in vitro after UV irradiation.
  • nucleus pulposus cells were plated out in a 96 well cell culture plate at a density of ca. 3000 cells/well and kept at 37°C, 5% C0 2 .
  • Cells were fed with 10%, 5%, 2.5%, 1.25% and 0.63% each of foetal bovine serum (FBS), ACS, platelet-rich plasma (PRP), plasma (identical to ACS but without incubation) and platelet lysate (PL).
  • FBS foetal bovine serum
  • PRP platelet-rich plasma
  • PL platelet lysate
  • Figure 7 shows percentages of living cells compared to non-supplemented controls 24 hours after supplement addition and UV irradiation. The data are based on the mean of three 96 well plates.
  • the supplements protected the cells to various degrees from UV irradiation induced cell death, depending on their concentration. This is shown by the percentages of living cells compared to the non-supplemented controls (right five columns), which were clearly above 100%. The maximum protection was achieved with 2.5% and 1.25% of FCS and 1.25% of ACS. The effects of PRP and plasma were less pronounced. A comparison between plasma and ACS showed that in certain concentrations incubation has a clear effect, but that a certain effect can also be achieved in the absence of incubation. Platelet lysate was not effective in this experiment.
  • UV irradiation causes net cell death in vitro. Supplementation with blood derived preparations clearly increases survival as compared to non-supplemented cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une préparation pharmaceutique pour utilisation par injection dans la peau, cette préparation pharmaceutique pouvant être préparée par un procédé de production comprenant les étapes consistant à utiliser un liquide prélevé dans un organisme, ce liquide comprenant des constituants cellulaires du sang, à utiliser un récipient ou un moyen formant enceinte, ledit récipient ou moyen formant enceinte présentant une surface interne, et à mettre ledit liquide en contact avec ledit récipient ou moyen formant enceinte, (a) ledit procédé de production comprenant en outre l'étape consistant à incuber ledit liquide dans ledit récipient ou ledit moyen formant enceinte pendant une certaine durée d'incubation et, éventuellement, à éliminer les constituants cellulaires de ce liquide après ladite incubation, (b) ledit liquide comprenant des exosomes, et ledit procédé de production comprenant en outre les étapes consistant à concentrer lesdits exosomes et, éventuellement, à éliminer les constituants cellulaires de ce liquide après ladite concentration, ou l'étape consistant à isoler lesdits exosomes, ou (c) ledit procédé de production comprenant en outre l'étape consistant à éviter l'incubation dudit liquide, et l'étape d'élimination des constituants cellulaires de ce liquide mis en contact avec ledit récipient ou moyen formant enceinte.
PCT/EP2016/001888 2015-11-13 2016-11-14 Préparation pharmaceutique efficace contre les troubles liés au vieillissement WO2017080669A1 (fr)

Priority Applications (47)

Application Number Priority Date Filing Date Title
IL259007A IL259007B1 (en) 2016-08-17 2017-05-11 Anti-aging preparations
MA042963A MA42963A (fr) 2016-08-17 2017-05-11 Préparation pharmaceutique anti-vieillissement
MX2019001948A MX2019001948A (es) 2016-08-17 2017-05-11 Preparacion farmaceutica anti-envejecimiento.
PCT/EP2017/000574 WO2018033226A1 (fr) 2016-08-17 2017-05-11 Préparation pharmaceutique anti-vieillissement
KR1020197003441A KR20190049690A (ko) 2016-08-17 2017-05-11 항-노화 약학 제제
CN201780003804.9A CN108348548A (zh) 2016-08-17 2017-05-11 抗衰老药物制剂
PE2019000304A PE20190627A1 (es) 2016-08-17 2017-05-11 Preparacion farmaceutica antienvejecimiento
US16/325,870 US20190290689A1 (en) 2016-08-17 2017-05-11 Anti-ageing pharmaceutical preparation
CR20190139A CR20190139A (es) 2016-08-17 2017-05-11 Preparación farmacéutica anti envejecimiento
BR112019002080-2A BR112019002080A2 (pt) 2016-08-17 2017-05-11 preparação farmacêutica antienvelhecimento
AU2017313163A AU2017313163B2 (en) 2016-08-17 2017-05-11 Anti-ageing pharmaceutical preparation
EP20155846.7A EP3695845A1 (fr) 2016-08-17 2017-05-11 Préparation pharmaceutique anti-âge
CA3033045A CA3033045A1 (fr) 2016-08-17 2017-05-11 Preparation pharmaceutique anti-vieillissement
SG11201900866YA SG11201900866YA (en) 2016-08-17 2017-05-11 Anti-ageing pharmaceutical preparation
JP2019508969A JP2019528281A (ja) 2016-08-17 2017-05-11 加齢防止製剤
EP17728051.8A EP3352769A1 (fr) 2016-08-17 2017-05-11 Préparation pharmaceutique anti-vieillissement
EA201890841A EA201890841A1 (ru) 2016-08-17 2017-05-11 Фармацевтический препарат против старения
US16/325,945 US20210290671A1 (en) 2016-08-17 2017-05-12 Anti-ageing pharmaceutical preparation
TW106115816A TW201806606A (zh) 2016-08-17 2017-05-12 抗老化醫藥製劑
SG11201901085RA SG11201901085RA (en) 2016-08-17 2017-05-12 Anti-ageing pharmaceutical preparation
MX2019001949A MX2019001949A (es) 2016-08-17 2017-05-12 Preparacion farmaceutica anti-envejecimiento.
EP20163717.0A EP3763377A1 (fr) 2016-08-17 2017-05-12 Préparation pharmaceutique anti-âge
MA042964A MA42964A (fr) 2016-08-17 2017-05-12 Préparation pharmaceutique anti-vieillissement
CR20190091A CR20190091A (es) 2016-08-17 2017-05-12 Preparación farmacéutica anti-envejecimiento
JP2019508931A JP2019529357A (ja) 2016-08-17 2017-05-12 加齢防止製剤
EP17728052.6A EP3352770A1 (fr) 2016-08-17 2017-05-12 Préparation pharmaceutique anti-vieillissement
PE2019000361A PE20190517A1 (es) 2016-08-17 2017-05-12 Preparacion farmaceutica antienvejecimiento
EA201890840A EA201890840A1 (ru) 2016-08-17 2017-05-12 Фармацевтический препарат против старения
BR112019002982-6A BR112019002982A2 (pt) 2016-08-17 2017-05-12 preparação farmacêutica antienvelhecimento e seu uso.
TW106115815A TW201806605A (zh) 2016-08-17 2017-05-12 抗老化醫藥製劑
CA3033899A CA3033899A1 (fr) 2016-08-17 2017-05-12 Preparation pharmaceutique anti-vieillissement
AU2017313164A AU2017313164B2 (en) 2016-08-17 2017-05-12 Anti-ageing pharmaceutical preparation
CN201780003805.3A CN108348549A (zh) 2016-08-17 2017-05-12 抗衰老药物制剂
PCT/EP2017/000581 WO2018033227A1 (fr) 2016-08-17 2017-05-12 Préparation pharmaceutique anti-vieillissement
KR1020197004442A KR20190046793A (ko) 2016-08-17 2017-05-12 항-노화 약학 제제
US16/325,944 US20190231816A1 (en) 2016-08-17 2017-08-17 Combination therapy effective in the treatment of ageing and age-related disorders
PCT/EP2017/000994 WO2018033249A1 (fr) 2016-08-17 2017-08-17 Polythérapie efficace dans le traitement du vieillissement et de troubles liés à l'âge
IL259006A IL259006A (en) 2016-08-17 2018-04-29 Anti-aging preparations
HK18114754.7A HK1255619A1 (zh) 2016-08-17 2018-11-19 抗衰老藥物製劑
HK19101111.1A HK1259143A1 (zh) 2016-08-17 2019-01-22 抗衰老藥物製劑
HK19101113.9A HK1258712A1 (zh) 2016-08-17 2019-01-22 抗衰老藥物製劑
PH12019550017A PH12019550017A1 (en) 2016-08-17 2019-01-30 Anti-Ageing Pharmaceutical Preparation
PH12019550022A PH12019550022A1 (en) 2016-08-17 2019-02-08 Anti-ageing pharmaceutical preparation
CONC2019/0001232A CO2019001232A2 (es) 2016-08-17 2019-02-12 Preparacion farmaceutica antienvejecimiento
CONC2019/0001265A CO2019001265A2 (es) 2016-08-17 2019-02-13 Preparacion farmaceutica antienvejecimiento
CL2019000419A CL2019000419A1 (es) 2016-08-17 2019-02-15 Preparación farmacéutica anti-envejecimiento
CL2019000420A CL2019000420A1 (es) 2016-08-17 2019-02-15 Preparación farmacéutica anti-envejecimiento.

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP15003234 2015-11-13
EP15003234.0 2015-11-13
EP15003285 2015-11-18
EP15003285.2 2015-11-18
EP16001807.3 2016-08-17
EP16001807 2016-08-17

Publications (1)

Publication Number Publication Date
WO2017080669A1 true WO2017080669A1 (fr) 2017-05-18

Family

ID=57517844

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2016/001888 WO2017080669A1 (fr) 2015-11-13 2016-11-14 Préparation pharmaceutique efficace contre les troubles liés au vieillissement
PCT/EP2016/001887 WO2017080668A1 (fr) 2015-11-13 2016-11-14 Préparation pharmaceutique efficace contre les troubles liés au vieillissement

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/001887 WO2017080668A1 (fr) 2015-11-13 2016-11-14 Préparation pharmaceutique efficace contre les troubles liés au vieillissement

Country Status (2)

Country Link
TW (2) TW201722443A (fr)
WO (2) WO2017080669A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018033226A1 (fr) * 2016-08-17 2018-02-22 Orthogen Ag Préparation pharmaceutique anti-vieillissement

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613424A1 (fr) 2018-08-23 2020-02-26 Orthogen AG Nouveaux procédés pour la production d'agents pharmaceutiques

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007529A2 (fr) * 2004-07-01 2006-01-19 University Of Pittsburgh Of The Commonwealth System For Higher Education Exosomes immunosuppresseurs
WO2012076193A1 (fr) * 2010-12-10 2012-06-14 Orthogen Ag Préparations combinées contenant des exosomes et un corticostéroïde
US20120237525A1 (en) * 2009-12-10 2012-09-20 Orthogen Ag Combination preparation including a cytokine antagonist and corticosteroid
US20140093545A1 (en) * 2012-09-28 2014-04-03 Orthogen Ag Antibacterial pharmaceutical preparation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007529A2 (fr) * 2004-07-01 2006-01-19 University Of Pittsburgh Of The Commonwealth System For Higher Education Exosomes immunosuppresseurs
US20120237525A1 (en) * 2009-12-10 2012-09-20 Orthogen Ag Combination preparation including a cytokine antagonist and corticosteroid
WO2012076193A1 (fr) * 2010-12-10 2012-06-14 Orthogen Ag Préparations combinées contenant des exosomes et un corticostéroïde
US20140093545A1 (en) * 2012-09-28 2014-04-03 Orthogen Ag Antibacterial pharmaceutical preparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. REY-RICO, J. REINECKE, P. WEHLING, M. CUCCHIARINI, H. MADRY: "Effects of exosomes upon the metabolic activities of human osteoarthritic articular cartilage in situ", OSTEOARTHRITIS AND CARTILAGE, vol. 23, no. 2, April 2015 (2015-04-01), pages A399, XP002766731, Retrieved from the Internet <URL:http://www.oarsijournal.com/article/S1063-4584(15)00780-3/pdf> [retrieved on 20170203], DOI: 10.1016/j.joca.2015.02.736 *
ALVAREZ-CAMINO J -C ET AL: "Use of autologous conditioned serum (Orthokine(R)) for the treatment of the degenerative osteoarthritis of the temporomandibular joint. Review of the literature", MEDICINA ORAL, PATOLOGIA ORAL Y CIRUGIA BUCAL 2013 MEDICINA ORAL, PATOLOGIA ORAL Y CIRUGIA BUCAL ESP, vol. 18, no. 3, May 2013 (2013-05-01), pages e433 - e438, XP002766741, ISSN: 1698-4447 *
BALTZER A W A ET AL: "Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis", OSTEOARTHRITIS AND CARTILAGE, BAILLIERE TINDALL, LONDON, GB, vol. 17, no. 2, 1 February 2009 (2009-02-01), pages 152 - 160, XP026018519, ISSN: 1063-4584, [retrieved on 20080731], DOI: 10.1016/J.JOCA.2008.06.014 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018033226A1 (fr) * 2016-08-17 2018-02-22 Orthogen Ag Préparation pharmaceutique anti-vieillissement
WO2018033249A1 (fr) * 2016-08-17 2018-02-22 Orthogen Ag Polythérapie efficace dans le traitement du vieillissement et de troubles liés à l'âge
WO2018033227A1 (fr) * 2016-08-17 2018-02-22 Orthogen Ag Préparation pharmaceutique anti-vieillissement
EP3763377A1 (fr) * 2016-08-17 2021-01-13 Orthogen AG Préparation pharmaceutique anti-âge

Also Published As

Publication number Publication date
TW201722442A (zh) 2017-07-01
WO2017080668A1 (fr) 2017-05-18
TW201722443A (zh) 2017-07-01

Similar Documents

Publication Publication Date Title
AU2017313163B2 (en) Anti-ageing pharmaceutical preparation
KR102147169B1 (ko) 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 가려움증 억제 또는 개선 용도
Velard et al. The effect of zinc on hydroxyapatite-mediated activation of human polymorphonuclear neutrophils and bone implant-associated acute inflammation
CN111148520A (zh) 包含脂肪干细胞来源外排体作为有效成分的组合物在减轻皮炎中的用途
Chakraborty et al. Impact of Treg on other T cell subsets in progression of fibrosis in experimental lung fibrosis
WO2017080669A1 (fr) Préparation pharmaceutique efficace contre les troubles liés au vieillissement
Sand et al. Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate
JP2022513335A (ja) 抗炎症及び免疫調節特性を有する臍帯血単核細胞に由来する小型細胞外小胞を含む組成物及びそれらを得るためのプロセス
CN114401729A (zh) 植物外泌体用于增强皮肤细胞的活力及毛发生长能力的用途
KR101636139B1 (ko) 면역조절능이 우수한 sRAGE 과발현 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
Yousefi et al. Investigation on the surface hydrophobicity and aggregation kinetics of human calprotectin in the presence of calcium
Bansal et al. A Short Study Report on Bone Marrow Aspirate Concentrate Cell Therapy in Ten South Asian Indian Patients with Autism.
EP4349348A1 (fr) Agent d&#39;amélioration de la cachexie cancéreuse et méthode d&#39;amélioration de la cachexie cancéreuse
KR20220000144A (ko) 엑소좀 군집 내에서 엑소좀 아집단을 분리하는 방법 및 이의 응용
WO2021161997A1 (fr) Polypeptide récepteur humain modifié de l&#39;interleukine 4 et agent d&#39;induction pour la différenciation ou la polarisation en m2-macrophages
KR102546187B1 (ko) 규조류 유래 후코잔틴을 포함하는 주름개선용 화장료 조성물
Matthews The Role of Tumor Necrosis Factor-α Reception on Dendritic Epidermal T Cell Activation and Function
Zargarani et al. Adipose‐derived mesenchymal stem cells ameliorates experimental autoimmune encephalomyelitis via modulation of Th1/Th17 and expansion of Th2/Treg responses
Glenn THE ROLE OF MESENCHYMAL STEM CELLS ON EFFECTOR CD8+ T CELL DEVELOPMENT AND NEUROINFLAMMATORY AUTOIMMUNE DISEASE
Moret et al. SAT0046 Intra-articular CD1C-expressing myeloid dendritic cells from RA patients express increased levels of T cell-attracting chemokines and induce TH1, TH2, and TH17 cell activity
Donders et al. CT-1266 Accepted 09/26/2014 for publication in “Cell Transplantation” Human Wharton’s jelly-derived stem cells display immunomodulatory properties and transiently improve rat experimental autoimmune encephalomyelitis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16808910

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16808910

Country of ref document: EP

Kind code of ref document: A1